Brolucizumab for Neovascular Age-Related Macular Degeneration in Real-World Setting

Keyphrases

• Neovascular Age-related Macular Degeneration (nAMD) 100%
• Brolucizumab 100%
• Subretinal Fluid 50%
• Intravitreal Injection 37%
• Retinal Thickness 37%
• Injection Interval 37%
• Nave 25%
• Real-world Clinical Practice 25%
• Inflammatory Events 25%
• Anti-VEGF Therapy 25%
• Neovascular AMD 25%
• Inflammation 12%
• Real-world Practice 12%
• Scopus 12%
• Functional Outcome 12%
• Severe Inflammation 12%
• In(III) 12%
• Clinical Trials 12%
• Thickness Reduction 12%
• PubMed 12%
• ScienceDirect 12%
• Visual Acuity 12%
• Thickness Change 12%
• Treatment Burden 12%
• Non-inferiority 12%
• Ocular Inflammation 12%
• Treatment Therapy 12%
• Disease Activity 12%
• Anatomical Outcome 12%
• ClinicalKey 12%
• Pigment Epithelial Detachment 12%
• Switch Therapy 12%
• Vascular Growth Factor 12%
• Early Treatment Diabetic Retinopathy Study 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Wet Macular Degeneration 100%
• Brolucizumab 100%
• Inflammation 37%
• Intravitreal Administration 37%
• Vasculotropin 25%
• Growth Factor 12%
• Observational Study 12%
• Clinical Trial 12%
• Diabetic Retinopathy 12%
• Disease Activity 12%
• Retina Detachment 12%
• Subretinal Fluid 12%

Medicine and Dentistry

• Wet Macular Degeneration 100%
• Brolucizumab 100%
• Intravitreal Administration 37%
• Vasculotropin 25%
• Clinician 12%
• Observational Study 12%
• Growth Factor 12%
• Clinical Trial 12%
• Diabetic Retinopathy 12%
• Visual Acuity 12%
• Disease Activity 12%
• Retinal Detachment 12%
• Vitreous 12%
• Subretinal Fluid 12%